NQO1-dependent anti-cancer drugs such as β-lapachone are attractive candidates for cancer therapy because several cancers, including cervix, breast, pancreas, colon, and lung, exhibit higher expression of NQO1 than adjacent tissues. This evidence concerns the gene NQO1 and cancer.